药物发现和开发的基本原则 1336条(本栏目收费,不能显示细节,电话15274084725)
Cytochalasin B, 357–358, 357f 357
Cytochrome P450 3A4 (CYP3A4), 348–349,360–362 362
Cytotoxicity, 354–356, 355f 355
chronic, 353–354, 376 376
Dalcetrapib (JTT-705), 12–13, 12f1,4-Diazepames CB2 agonists, 282–283 283
tomography (SPECT), 427–428,427t 427
sleep/wake cycle, 435 435
X-ray computed tomography (X-ray CT), 425 425
mechanism biomarkers, 419 419
outcome biomarkers, 419–420 420
pharmacogenomic biomarkers, 420 420
vs. surrogate end points, 423–424 424
target engagement biomarkers, 419 419
toxicity biomarkers, 420 420
Biopharmaceutics Classification System (BCS), 262, 262f 262
Biotin, 153–154, 153f 153
Bupropion, 521–522, 521f 521
California Institute for Biomedical 0
Research (Calibr), 463–464 464
cAMP signaling. See Cyclic adenosine 0
monophosphate (cAMP) signaling 0
Cardiovascular disease animal model. See 0
Animal models, disease states, 0
cardiovascular disease animal 0
Cardiovascular safety and toxicology 0
acute cardiovascular safety, 369 369